FeMn single-atom nanozyme dual-readout HER2 test
An etched FeMn–N–C nanozyme boosts peroxidase-like activity 2.03-fold and reports HER2 by electrochemistry and 808 nm photothermal readout.
Source
Bimetallic Single-Atom Nanozyme-Based Electrochemical-Photothermal Dual-Function Portable Immunoassay with Smartphone Imaging
What they did
Authors pyrolyzed ZnO@ZIF-8 to N-doped carbon, doped Fe/Mn, etched defects, assayed TMB/H2O2 POD activity, built a sandwich immunoassay, and compared five hospital sera to ELISA.
What they found
FeMn-NCetch/SAC is 2.03× more POD-active than Fe-NC/SAC. Dual electrochemical and 808 nm photothermal signals agree with a commercial HER2 ELISA (texp < 2.78).
The limits
What it doesn't show
This is a five-sample serum comparison, not a multicenter diagnostic trial; ‘biotherapeutic’ potential is speculative.
Key terms
- Single-atom nanozyme
- M–N–C sites that mimic peroxidase (POD) activity.
- POD-like activity
- Catalysis of TMB oxidation by H2O2, read at 652 nm.
- HER2
- Breast-cancer biomarker detected in the sandwich assay.
- Photothermal readout
- 808 nm laser heating used as a second signal channel.
- Dual-readout immunoassay
- Independent electrochemical and thermal signals for the same capture event.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
POD-like activity rose by about:
Common questions
How much did bimetallic etching help POD activity?
2.03 times vs Fe-NC/SAC.
Second signal?
808 nm photothermal with a digital multimeter.
Clinical check?
Five sera vs commercial ELISA, t below 2.78.
TMB readout wavelength?
652 nm.
More on Electrochemistry